Clinical trial
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor…
NCT00363467 · H. Lee Moffitt Cancer Center and Research Institute, Other · Terminated
Key facts
| NCT number | NCT00363467 |
|---|---|
| Title | Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation |
| Official title | A Pilot Study of Intravenous, Targeted-Dose Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation in High-Risk AML |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | ESP Pharma |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia (AML) |
| Intervention type | Drug, Procedure |
| Interventions | G-CSF, Leukapheresis, Busulfan, Stem cell reinfusion |
| Enrollment | 3 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Aug 15, 2006 |
| Last update posted | Mar 23, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: